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ABSTRACT 
The main use of MRS is for the assessment of metabolism in vivo; that is because it has the 
unique ability to monitor metabolism noninvasively without the use of ionizing radiation.  
In recent years MRS has also become widely used for metabolomics, the science that 
aspires to monitor the metabolome – the totality of small-molecule metabolites in an 
organism, a cell or a disease. This chapter discusses the properties of MRS that make it 
suitable for metabolomic studies and the reasons why they are mainly performed ex vivo, as 
well as the methods used for preparing samples, performing the MRS and analyzing the 
resulting data.  Further sections discuss MRS detection of metabolic aspects of the common 
cellular processes apoptosis, necrosis and autophagy.  A final section summarizes metabolic 
studies of some diseases by MRS: cancer, cardiovascular disease, neurological and 
neurodegenerative diseases, and muscle disease.   
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 1.     INTRODUCTION 
1.1. Metabolism and Metabolomics  
Most of this book is concerned with the use of MRS to study aspects of metabolism in 
vivo, a situation where the MRS method has the unique advantage of detecting and 
quantifying metabolites non-invasively without the use of ionizing radiation.  Over the 
last 15 years however, a related topic has developed – “Metabolomics” – and this too 
has been studied by MRS methods.  Whereas metabolic biochemistry usually focusses 
on individual reactions or pathways, metabolomics is the study of the totality of small 
molecule metabolites (the “metabolome”) in an organism. It has recently taken a place 
alongside the more familiar “omics” sciences of genomics, transcriptomics and 
proteomics.  There are thought to be several thousand metabolites (i.e. low molecular 
weight chemical compounds) in a typical cell, and their concentrations at any moment 
in time constitute the metabolome.  All of the enzymes and some of the other proteins 
coded by the genome ultimately have their effect on the phenotype of the organism by 
influencing the concentrations of its metabolites, so the metabolome is an important 
target of research. 
 Note that like the proteome and transcriptome, but unlike the genome, the 
metabolome is state-specific, so that one can speak for instance of the metabolome of 
an individual cell within an organism or the metabolome of a disease state.  
Furthermore, the metabolome is much less stable than even the proteome: the 
concentrations of metabolites within it can vary over minutes or even seconds in 
response to external stimuli (e.g. the stimulus to contract a muscle simultaneously 
initiates breakdown of glycogen as a fuel) or to homeostatic interactions between the 
metabolites in metabolic pathways themselves.  At present it is not possible to measure 
more than a few hundred of the metabolites in the metabolome; those subsets that can 
be measured are often termed “metabolic profiles”.   
 
1.2. Advantages of MRS for metabolomics 
There has been an explosion of interest in the use of NMR-based methods to study the 
metabolome over the last decade (see Fig 1).  This is because NMR and MRS have 
many advantages for metabolic studies, both in vivo and ex vivo. As has already been 
mentioned, in vivo studies by MRS can detect metabolites non-invasively, which is 
often a crucial advantage for studying individual metabolic reactions.  However, only a 
small number of metabolites present at high concentration can be measured in vivo 
because of the relative insensitivity of MRS at the magnetic fields that can be used and 
the broad spectral lines that are observed. In order to detect as many metabolites as 
possible, metabolomic studies are often performed by ex vivo MRS methods on 
samples such as tissue biopsies and cultured cells. Such spectra give higher sensitivity 
because higher fields and longer scan times can be employed, as well as better spectral 
resolution. Note that these ex vivo MRS methods are often termed “NMR” methods, 
since they are usually performed on vertical-bore high-resolution NMR instruments; 
however we will retain the term MRS since it is used elsewhere in this book, and since 
the two methods are fundamentally identical.  We will not deal with measurements of 
metabolites in body fluids (see emrstm1048).   
 Even when used on ex vivo specimens, MRS is much less sensitive than mass 
spectrometry (MS), the main competing analytical method in metabolomics. However, 
it has some compensating advantages.  Preparation of a tissue sample for MRS involves 
a simple extraction or, for HR-MAS (high-resolution magic angle spinning; see 
emrstm1231) MRS, simply placing the solid sample in a rotor insert.  The subsequent 
MRS procedure then quantifies all of the metabolites in that extract or intact sample so 
that any quantification errors will usually cancel out and the relative amounts of the 
metabolites will be detected with good precision.  Furthermore, the HR-MAS method is 
non-destructive, and even after extraction the metabolites in the sample are available 
for subsequent studies.  MS methods, in contrast, require preliminary separation of the 
metabolites within the samples, usually by liquid chromatography (LC-MS) or gas 
chromatography (GC-MS).  Before performing GC-MS it is usually necessary to 
derivatize the metabolites in order to make them volatile.  Quantification errors may be 
introduced by the separation process and particularly by the derivatisation.  Lastly, the 
MS procedure itself involves ionization of the metabolites (or their derivatives) and 
further errors can be introduced if ionization is incomplete.   
<Fig 1 near here> 
 
Thus although ex vivo MRS methods are usually able to quantify a metabolic profile of 
only 20-30 high-concentration metabolites, they do so with great precision and 
reproducibility, an advantage that makes them particularly suited to studies in which the 
metabolome of a cell or organism is perturbed and then compared with the original 
metabolome.   
 
2. Ex Vivo MRS Methods for studying the metabolome 
The broad MR spectral lines observed in vivo (see Fig 2A) are also seen when spectra are 
obtained ex vivo from solid tissue biopsies or cultured cells.  There are two solutions to 
that problem: HR-MAS MRS (Fig 2B) or extraction of the metabolites into solution (Fig 
2C).  HR-MAS MRS involves spinning the solid sample in a rotor at a “magic angle” 
relative to the main magnetic field (see section 2.2 below and emrstm1231).  That 
eliminates the broadening processes caused by dipole-dipole interactions, giving a 
spectrum with peaks that are adequately resolved.  
1
H HR-MAS MRS is by far the most 
commonly used method here. Performing MRS on extracted metabolites in solution in a 
high-resolution instrument narrows the spectral linewidths still further due to the motional 
narrowing, as shown in Fig 2C. 
<Fig 2 near here> 
2.1. Preparation of tissue or cell extracts for MRS 
Living tissues or cultured cells can be prepared for MRS by extraction with a liquid that 
denatures the tissue proteins. This inactivates the enzymes that would otherwise 
scramble the metabolite concentrations, and also releases into solution metabolites that 
were bound to proteins or sequestered in organelles.  The denatured proteins are spun 
down and the supernatant is removed, neutralized, freeze-dried and re-dissolved in D2O 
(deuterated water) for analysis by MRS.  An external standard is normally added to the 
extract to permit chemical shift standardization and quantification. 
Because post-mortem scrambling of metabolites and even simple chemical 
breakdown can occur within a few seconds of tissue death, it is routine in metabolic 
biochemistry to freeze tissue samples instantly by crushing them between liquid-
nitrogen-cooled blocks mounted on tongs (“freeze-clamping”).  In cell culture work an 
additional problem occurs: procedures such as stripping cells from a culture plate or 
bottle (e.g. with trypsin) and then spinning them down in a centrifuge tube, are quite 
time-consuming and likely to alter the metabolism of the cells.  It is best, therefore to 
remove the culture medium quickly, add the extraction medium to the culture plate or 
bottle and then scrape the cells directly into the denaturing liquid. 
The classic extraction medium in metabolic biochemistry is 5% perchloric acid, 
which has the advantage that it can subsequently be removed by precipitation as 
potassium perchlorate.  It is very efficient at denaturing enzymes but it releases 
artefactual chemicals from the plastic tissue culture plates or bottles
1
.  If allowance is 
made for these artefacts it is still a very reliable method. 
The other main class of extraction media is organic solvents.  Chloroform-
methanol-water 1:1:1 mixtures have been used for more than half a century to extract 
lipids from tissues
2
. A homogenate tissue and the extraction medium is centrifuged and 
the supernatant separated into two phases with the lipids in the lower chloroform layer, 
and the polar compounds (including most of the metabolites) in the upper 
methanol/water phase.  More recently, Leibfritz’s group3 developed this method into a 
combined extraction technique for both water-soluble metabolites and lipids.  Another 
organic solvent that is sometimes used for tissue extraction is acetonitrile.  
 
2.2. HR-MAS MRS 
To obtain a metabolite spectrum from a solid tissue sample by HR-MAS MRS, it is 
simply necessary to pack the sample into a rotor insert. The spectrum is obtained 
while the sample is spun at several thousand rpm at the “magic angle” (ca. 54.74°).  
An advantage of this method is that no extraction procedure is required and the 
sample remains largely unharmed at the end of the experiment so that it can be used 
again, e.g. for gene expression or histological studies.  
 
2.3. MRS studies of metabolite uptake and output 
MRS methods are particularly useful for measuring the uptake and output of 
metabolites from cultured cells.  Since cell culture medium has to be changed every 
few days one simply freeze-dries samples of the used and unused culture media, re-
dissolves them in D2O and obtains MRS spectra.  Most cultured cells take up energy 
substrates such as glucose and glutamine and secrete products such as lactate. 
However, many other metabolites enter or leave the cells in relatively small amounts.  
By calculating the carbon content of the metabolites entering and leaving the cell one 
can perform a carbon balance study that gives an indication of the fuels used by the 
cells.  More elaborate metabolic flux studies can be done using labelled substrates 
both ex vivo and in vivo (see emrstm1468). 
 
2.4. Metabolites that can be quantified by MRS ex vivo 
Table 1 shows the metabolites that are routinely quantifiable in 
1
H, 
13
C or 
31
P MRS 
spectra of living tissues.  This list is not exhaustive: some metabolites are found only in 
certain tissues: N-acetylaspartate, for instance, is mainly found in the brain and citrate 
in the prostate.  Intracellular metabolites in cell cultures can be quantified relative to 
cell numbers, cell volume or protein content; metabolites measured in tissue samples 
can be normalized to tissue wet weight or protein concentration. 
 
2.5. Pulse sequences for ex vivo MRS  
1
H MRS metabolite profiles are usually obtained with solvent suppression pulse 
sequences such as pre-saturation (e.g. pulse sequence “zgpr” on Bruker NMR 
software) or 1D-NOESY (nuclear Overhauser effect spectroscopy, emrstm0347).  
Other 2D-MRS methods such as COSY (correlation spectroscopy, emrstm0096), 
HSQC (heteronuclear single quantum coherence spectroscopy, emrstm0563) and 
TOCSY (total correlated spectroscopy, emrstm1165) can then be used for 
confirmation of the assignments of the metabolites
4
. The broad signals of lipids and 
macromolecules that appear in 
1
H HR-MAS MRS spectra of tissue samples can be 
filtered out with a pre-saturated CPMG (Carr-Purcell-Meiboom-Gill) pulse sequence, 
which is commonly used as a T2-filter. Similarly, a diffusion-weighted filter 
(stimulated-echo pulse sequence with pulsed gradients - STE-PG) can be used to 
filter out the low-molecular weight metabolite signals from the lipid and 
macromolecular signals
4
. 
 
2.6. Data processing for ex vivo MRS  
 Phase correction and baseline correction are routinely employed in the pre-processing 
of metabolite profiles. Metabolites are then initially identified by measuring their 
chemical shifts relative to internal standards such as trimethylsilyl propanoic acid (TSP) 
or 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) Three broad methods of spectral 
analysis are employed in metabolomic studies.  
2.6.1. Metabolite  fingerprinting (the chemometric approach) 
Most metabolomic studies on clinical specimens use chemometric methods as 
the matrix of data can be huge, with many dependent and independent variables, 
thus requiring reduction in data dimensionality. The initial pre-processing of the 
spectra involves normalization of the peaks to a standard, followed by “binning” 
(or “bucketing”) of the spectrum – i.e. dividing the chemical shift range into a 
number of bins and measuring the area of the peaks in each bin. Binning 
eliminates small alterations in the chemical shifts of the peaks due to factors 
such as pH, ionic strength or temperature.  The bins should ideally be wide 
enough to encompass the whole of a peak but not so large that they take in more 
than one peak. 
 
The spectra are then initially analyzed by unsupervised pattern 
recognition methods such as Principal Component Analysis (PCA, see 
emrstm1472) to identify general trends and outlier samples, followed by 
supervised methods such as Partial Least Squares-Discriminant Analysis (PLS-
DA) or Orthogonal Partial Least Squares-Discriminant Analysis (OPLS-DA)
5
 
which can give better separation (see Fig 3). These methods are increasingly 
applied in the metabolomics field where the biomarkers (classifiers) can be 
useful in classifying groups (e.g. health vs disease or control vs treated) based on 
their metabolite profiles. Samples must be collected and processed in an 
identical manner for these studies.  
<Fig 3 near here> 
2.6.2. Quantitative metabolomics (Metabolite Profiling)  
In contrast to the chemometric approach described above, in quantitative 
metabolomics the metabolites are identified from metabolite libraries and 
quantified. Metabolites can be quantified in terms of absolute concentrations 
(e.g. mmol/l or mg/g protein) by integrating the areas under the metabolite peaks 
and then comparing them with that of an added internal reference compound of 
known concentration, making allowance for the number of spins contributing to 
each peak. Absolute concentrations of metabolites are useful in systems biology 
studies, particularly when metabolomic data need to be combined or correlated 
with other global profiling data (e.g. transcriptomic or proteomic data) from the 
same biological samples. This is also a better strategy than chemometrics when 
the samples cannot be collected and processed in an identical manner.   
 
2.6.3. Metabolite target analysis (Isotopomer analysis) 
This approach focuses on metabolites in a particular metabolic pathway, 
enabling dynamic metabolic flux analysis. Substrates
 
labelled with
 13
C can be 
traced through a metabolic pathway by 
13
C MRS. Due to the lower sensitivity of 
13
C MRS methods and the high costs of labelled substrates, this approach has not 
been very popular until recently.  However, its future looks promising because of 
recent developments in hyperpolarized 
13
C MRS protocols (see emrstm1457, 
1468, 1253).  
 
3. MRS OF CELLULAR PROCESSES 
3.1. Apoptosis 
An accumulation of the –CH2–CH2–CH2– lipid groups is associated with apoptosis in 
cancer cells in culture, but the presence of this lipid resonance has been found to 
coincide with areas of necrosis (rather than apoptosis) in solid tumors.  The 
1
H MRS 
visible lipids were found to accumulate and to increase their degree of lipid saturation 
in solid tumors during apoptosis. These lipids are attributed to cell constituent 
breakdown products that form lipid vesicles in dying cells
6
.  Changes in 
phosphocholine (PC), glycerophosphocholine (GPC) and taurine, measured by 
1
H 
MRS, have also been reported to be associated with apoptosis (emrstm1093).  
Decreased hyperpolarized [1-
13
C]pyruvate to [1-
13
C]lactate exchange,  measured 
by 
13
C MRS, was found to be associated with apoptosis induced by etoposide 
treatment in EL-4 murine lymphoma xenografts. These changes were caused by the 
activation of poly(ADP)-ribose polymerase (PARP) during apoptosis, which led to 
depletion of the nicotinamide adenine dinucleotide (NAD+, NADH) pool
7
 
(emrstm1093).   
3.2. Necrosis 
Accumulation of MR-visible lipids has been found in necrotic regions of tumors by 
1
H MRS
6
.  The conversion of hyperpolarized [1,4-
13
C]fumarate to [1,4-
13
C]malate 
measured by 
13
C MRS has been found to be a marker of necrosis. (emrstm1093).  
3.3. Autophagy 
Decreases in lactate secretion and in the hyperpolarized 
13
C-labelled pyruvate to 
lactate exchange rate are found in cells and tumors undergoing treatment- and 
starvation-induced autophagy.  The underlying mechanisms are thought to involve an 
increase in the NAD+/NADH ratio in drug-induced autophagy
8
 and a decrease in 
lactate dehydrogenase activity in starvation-induced autophagy
9
. 
 
4. METABOLOMIC STUDIES OF DISEASES                                                                                          
4.1. Cancer Metabolomics: 
Reprogramming of energy metabolism has been defined as an emerging hallmark of 
cancer
10
. It is distinguished by the “Warburg effect”, a shift in energy production from 
oxidative phosphorylation to glycolysis even when oxygen is freely available.   To 
support tumor growth and proliferation, cancer cells have increased glucose uptake, 
lactate production, phospholipid turnover and glutamine metabolism.  Many 
important genetic mutations (e.g., p53, 5′adenosine monophosphate-activated protein 
kinase (AMPK), hypoxia-inducible factor (HIF)), oncogenes (e.g., Ras and c-Myc) 
and signaling pathways (e.g., PI3K/AKT/mTOR and MAPK/ERK) have been found 
to regulate these processes and to aid development and progression of cancer
11
.  
Numerous anticancer therapies, such as inhibitors of phosphoinositide 3-kinase 
(PI3K), protein kinase B (AKT), HIF-1, pyruvate dehydrogenase kinase, choline 
kinase, glucose transporter-1 (Glut-1) or monocarboxylate transporter-1 (MCT-1), 
target these metabolic abnormalities in cancer. 
MRS methods, both in vivo and ex vivo, can be used to examine the 
reprogrammed tumor metabolism and signaling pathways that support tumor growth, 
and to aid the development of pharmacodynamic biomarkers that could potentially 
assess response to therapy or the emergence of tumors resistant to therapy. Such 
information could be useful in clinical trials and for individualising therapy
12
.  
Metabolomic MRS has also been investigated for diagnosing and grading many 
cancer types, for example, prostate
13
 (see emrstm1433), brain
14
 (emrstm1425), 
cervix
15
, lung
16
, and breast
17
 (emrstm1424), as well as examining the effect of cancer 
on host organs
18
.   
 
4.1.1. Glycolytic metabolism 
Aerobic glycolysis (the Warburg effect) is a well-known phenomenon in cancer, and 
the rate of glycolysis appears to be associated with the differentiation status and 
growth rate of the tumor
19
.  In vivo 
1
H and 
13
C MRS (together with 
13
C-enriched 
substrates) can be used non-invasively to examine and monitor the glycolytic 
behavior of different tumor types and their response to treatment.   Lactate production 
can be measured in vivo by 
1
H MRS using a multiple-quantum-coherence–edited 
sequence or by 
13
C MRS using a 
13
C-enriched substrate, such as, glucose 
[emrstm1253], both in the steady-state and in real time (by Dynamic Nuclear 
Polarization (DNP).  Lactate can be measured ex vivo by 
1
H HR-MAS MRS on tumor 
biopsies or high-resolution 
1
H MRS on extracts. In vivo 
13
C MRS measurement of 
hyperpolarized 
13
C-labelled [1-pyruvate]–to–lactate exchange has been used to 
measure real-time flux of pyruvate to lactate non-invasively, both in preclinical 
models and in patients [emrstm1253].   
Over-expression of the hypoxia inducible transcription factors HIF-1 and HIF-2 
has been found in many cancers and can cause an increased rate of glycolysis and 
glucose metabolism.  In vivo and ex-vivo 
1
H MRS have been used to study the effects 
of these transcription factors. For example, overexpression of HIF-2α resulted in 
tumors with higher glucose and lower lactate and alanine levels, together with faster 
tumor growth and increased pyruvate dehydrogenase and lower pyruvate 
dehydrogenase kinase-1 expressions, all indicating that these tumors maintain their 
growth rate by reducing glycolysis and increasing mitochondrial metabolism
20
. 
Real-time lactate measurement by DNP 
13
C MRS has been used to examine the effect 
of signaling pathway inhibition on the Warburg effect in tumors; for example, 
reduced [1-
13
C]pyruvate to [1-
13
C]lactate exchange, together with decreased lactate 
dehydrogenase activity, were found in glioblastoma xenografts and orthotopic tumor 
models following treatment with the PI3K inhibitor LY294002 or the mTOR inhibitor 
Everolimus
21
 .   
 
4.1.2. Tricarboxylic Acid Cycle metabolism 
Recently there has been renewed interest in glutamine metabolism and that of various 
tricarboxylic acid (TCA)-cycle intermediates in cancer.  An MRS study of 
13
C-
labelled substrates showed that glutamine was used as the major anaplerotic precursor 
in proliferating cancer cells
22
.  In tumors with mutations of the TCA-cycle enzymes 
succinate dehydrogenase and fumarate hydratase (FH) the intermediates succinate and 
fumarate accumulate. Both of these have been found to act as oncometabolites that 
enhance tumor growth and survival during stress by mechanisms that include 
activation of HIF-1. Increases in fumarate level and lactate production, together with 
upregulated HIF-1 target genes, were observed in FH-deficient tissues isolated from 
FH-deficient mice
23
, which is consistent with the 
1
H-MRS metabolic profiles of FH 
deficient cells
24
.  
Mutation of the TCA cycle enzyme isocitrate dehydrogenase (IDH1) induces a 
gain of function allowing it to synthesize the oncometabolite 2-hydroxyglutarate (2-
HG) instead of α-ketoglutarate (α-KG). 2-HG accumulates at millimolar 
concentrations in some gliomas and can be detected by 
1
H MRS in vivo
25
.  In vivo 
13
C 
MRS of hyperpolarized [1-
13C]α-KG has also been used on gliomas to examine the 
effect of IDH1 gene mutation on the formation of 2-HG. This mutation is associated 
with a decrease in the activity of branched-chain amino acid transaminase-1 
(BCAT1), the enzyme that catalyzes the transamination of branched-chain amino 
acids while converting α-KG to glutamate.  Only [1-13C]α-KG was observed in IDH1 
wild-type glioma tumors, whereas, hyperpolarized [1-
13
C]2-HG was found in IDH1 
mutant orthotopic tumors
26
.  A lower conversion rate of hyperpolarized [1-
13C]α-KG 
to hyperpolarized [1-
13
C]glutamate was also found in the IDH1 mutant tumors, 
consistent with reduced BCAT1 activity
27
 . 
 
4.1.3. Tumor bioenergetics and pH  
In vivo 
31
P MRS has been used to study tumor bioenergetics and tumor pH non-
invasively, by measuring metabolites such as nucleoside triphosphates (NTP), 
phosphocreatine (PCr) and inorganic phosphate (Pi).  Intracellular pH (pHi) is 
measured from the chemical shift between the Pi resonance (pH-sensitive) and a pH 
insensitive resonance of a metabolite such as, PCr or NTP (see emrstm1458).  A 
decrease in high-energy phosphates (NTP and PCr) and increased Pi, together with a 
more acidic pHi have been found in hypoxic tumors. Hypoxia can develop when 
tumor growth exceeds the blood supply or when reduced micro-vessel density 
develops following therapy
28
.   
 
4.1.4. Membrane metabolism 
Increased growth and proliferation in tumors requires elevated membrane synthesis 
and turnover.  Phospholipids are major membrane components and are also involved 
in the regulation of cell function and signaling pathways. Choline-containing 
phospholipid membrane components can be detected by MRS, and they have been 
used to aid diagnosis and prognosis in cancer
29
 (see also emrstm1425).  In vivo 
1
H 
MRS provides information on the total choline level, which includes signals from free 
choline, phosphoethanolamine (PE), PC, GPC and glycerophosphoethanolamine 
(GPE), whereas in vivo 
31
P MRS detects a peak from phosphomonoesters (PME, 
comprised of PE and PC) and another peak form phosphodiesters (PDE, comprised of 
GPC and GPE).  An increase in PME has been attributed to increased membrane 
synthesis, often associated with rapid tissue growth, whereas the PDE resonance is 
associated with membrane breakdown.  Increased choline-containing compounds or 
the total choline level have been used as endogenous biomarkers that distinguished 
between benign and malignant tumors in many types of human cancers
29
.  Assessment 
of phospholipid metabolism by MRS could also provide insights into tumor response 
following treatment (emrstm1093).  
PC is involved in cell membrane synthesis and is formed by the phosphorylation 
of choline, catalyzed by choline kinase (ChoK).  Increased levels of PC and ChoK are 
associated with cell proliferation and malignant transformation in tumors, and 
inhibition of ChoK results in reduced PC levels
29
.  Changes in phospholipid 
metabolites have also been found by MRS, both in vivo and in tumor extracts, 
following treatment with conventional cytotoxic therapies and experimental 
anticancer drugs (emrstm1093).  Reduced PC was also found in tumors with HIF-1 
deficiency when compared with wild-type controls (emrstm1093).   
 
4.1.5. Lipid metabolism 
MR-visible lipid (or mobile lipid) signals arise from cytosolic lipid vesicles that are 
present in both proliferating and malignant cells; they have been found by 
1
H MRS in 
a variety of tumors, both in vivo and in tissue extracts ex vivo. The MR-visible lipids 
are comprised of triglycerides and cholesterol esters in intracellular neutral lipid 
droplets. Increased lipid signals from droplets are found in tumors under stress or 
undergoing apoptosis and necrosis following therapies.  The underlying reasons for 
the higher level of lipids and the mechanisms that control the production of lipid 
droplets are currently under investigation
6
. It has been suggested that they may play a 
role in detoxifying the cells under stress or act as an alternative energy source
6
.   
Inhibition of fatty acid synthase, an enzyme that catalyzes the terminal steps in 
the synthesis of saturated fatty acids, by the fatty acid synthase inhibitor Orlisat 
resulted in reduced levels of fatty acids as measured by 
1
H and 
31
P 
MRS(emrstm1093).   
 
4.2. Cardiovascular Disease 
Metabolomic studies by MRS have been used in cardiovascular diseases to develop 
biomarkers for diagnosis and prognosis, for predicting disease progression and 
treatment response, and for identifying treatment targets30.  In vivo 1H MRS can be 
used to measure the total creatine level in heart tissues and in vivo 
31
P MRS is used to 
examine heart bioenergetics and creatine kinase flux in cardiac diseases and 
dysfunction
31,32
.  Intramyocardial triglyceride content in human subjects can also be 
measured by in vivo 
1
H MRS [see emrstm1453].  HR-MAS MRS has identified taurine 
as a potential biomarker for myocardial infarction
33
 and this method has also been used 
to examine the acute effect of 3,4-methylenedioxymethamphetamine on cardiac 
metabolism in the rat
34
. Non-invasive DNP studies are used to assess metabolism in 
cardiovascular disease in vivo
35, 36
.  [1-
13
C]pyruvate has been the most widely studied 
substrate to date because of its central role in cellular metabolism. Combined used of 
hyperpolarized [1-
13
C]- and  [2-
13
C]-pyruvate has resulted in significant advances in the 
understanding of real time myocardial metabolism in the normal and diseased heart in 
vivo, as TCA cycle metabolism can also be assessed
35,36
. In addition to pyruvate, 
hyperpolarized 
13
C-labelled bicarbonate
 
has been used to measure extracellular pH in 
the perfused rat heart after ischemia
35-36
. 
1
H MRS based metabolomics has been combined with proteomics in the 
investigation of gene manipulation and ischemic preconditioning of smooth muscle 
cells and heart tissues; it showed that a deficiency of either PKC-ε or PKC-δ was 
sufficient to abrogate the cardioprotective effects of ischemic preconditioning
37,38
. In 
another study from the same group, proteomic and ex vivo 
1
H MRS metabolomic 
analysis of aortas from apolipoprotein E(apoE) mice demonstrated that inefficient 
vascular glucose and energy metabolism coincides with increased oxidative stress in 
hyperlipidemic animals, as evidenced by oxidation of redox-sensitive proteins
39
. 
Similar studies combining 
1
H MRS-based metabolomics with proteomics have been 
performed on biopsies from the human heart
40
.  
 
4.3. Neurological Disorders and Neurodegenerative Diseases  
 Localized in vivo 
1
H MRS can detect many metabolites non-invasively in human 
brain, including N-acetylaspartate (NAA), creatine and phosphocreatine, choline, myo-
inositol, lipids, lactate and glutamate/glutamine/GABA
41
 (see also emrstm1449).    
NAA and myo-inositol are regarded as neuronal and glial biomarkers, respectively, 
while creatine and phosphocreatine are involved in the bioenergetic pathways and the 
choline signal provides information about membrane turnover. Glutamate is a 
neurotransmitter and plays an important role in brain function
42
 while lactate is 
involved in the glycolytic activity of the brain.  These MRS-detectable metabolites are 
found to alter in many neurological disorders and neurodegenerative diseases, both in 
human patients and in animal models, e.g., brain injuries, stroke, Parkinson’s disease, 
multiple sclerosis, schizophrenia, Alzheimer’s disease and) prion diseases such as 
transmissible spongiform encephalopathy
43-46
.  In vivo 
31
P MRS has been used to assess 
the bioenergetic status of the brain, as the high-energy phosphates (PCr and NTP), Pi 
and intracellular pH (as noted above) are modulated in neurological conditions such as 
hypoxic-ischemic brain injury
43
.  
   
In tissues of individuals with schizophrenia, 
1
H HR-MAS MRS combined with 
proteomic and transcriptomic data have shown increased glycolytic flux when 
compared to the corresponding tissues from individuals with bipolar disorder
47
. In a 
study of ex vivo 
1
H HR-MAS MRS of human brain biopsies, Cheng et al showed a 
linear relationship between neuronal count (neuronal density) and NAA, and found that 
metabolite ratios are better than neuronal counts in the diagnosis of Alzheimer’s 
disease
48
. Further details concerning the use of MRS to monitor metabolism in 
neurology and neurological diseases can be found in emrstm1449, emrstm1464, 
emrstm1491 and emrstm1463. 
 
4.4. Muscle Diseases 
In vivo 
31
P MRS is commonly used to assess the bioenergetic status and function of 
resting and exercising muscle, as resting muscle contains high levels of PCr and ATP, 
and during exercise the muscle PCr level and intracellular pH decrease, accompanied 
by an increase in muscle Pi
49
.  Studies have been performed during rest and exercise in 
many diseases, e.g., muscular dystrophy; myositis and scleroderma
50-53
, and to monitor 
treatment response
54
.  The absolute concentrations of phosphorylated metabolites in 
muscles with different fiber composition have been determined in vivo by localized 
31
P 
MRS in the rat hind limb
55
. Attempts have also been made to quantify the absolute 
concentration of phosphorus metabolites in human muscle
56
.  
1
H MRS has been applied 
to study lipid metabolism in muscle.  
1
H MRS can measure intramyocellular lipids
57
 
which have been found to play a role in the development of insulin resistance
58
 and 
metabolic abnormalities
59
.  Further details concerning the use of MRS for examining 
muscle metabolism can be found in emrstm1442 and emrstm1431. 
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Metabolites Quantifiable by 
1
H MRS ex vivo 
Glycolytic Metabolites 
α-Glucose β-Glucose Lactate Pyruvate 
 
Amino Acids and Associated Metabolites 
Alanine Asparagine  Aspartic Acid Glutamate 
Glutamine Glycine Histidine iso-Leucine 
Leucine Lysine Phenylalanine Serine 
Threonine Tyrosine Taurine Valine 
α-Ketoisovalerate Glutathione N-acetyl aspartate  
 
Membrane-Associated Metabolites 
Choline Phosphocholine Glycerophosphocholine Phosphoethanolamine 
Dimethylamine Betaine Cholesterols & esters Phosphatidylcholine 
Phosphatidyl-
ethanolamine 
Phosphatidyl-
glycerol 
Glycerol  
Plasmalogen Triacylglycerol Myo-inositol Scyllo-inositol 
 
Energy Metabolites 
ATP & ADP Creatine Phosphocreatine NAD
+
 & NADH 
Inosine UTP & UDP   
 
TCA Cycle & Related Metabolites 
β-hydroxybutyrate Fumarate Succinate Acetate 
Citrate    
 
Table 1.  Metabolites routinely quantifiable by 
1
H MRS in living tissues.  
  
Table 2. Databases used in metabolomics studies 
NMR spectra data bases 
Name  URL 
Spectral Database for Organic Compounds  (SDBS) http://sdbs.db.aist.go.jp/sdbs/cgi-bin/cre_index.cgi 
Biological Magnetic Resonance Data Bank (BMRB) http://www.bmrb.wisc.edu/ 
NMRshiftDB http://nmrshiftdb.nmr.uni-koeln.de/ 
Madison Metabolomics Consortium Database (MMCD) http://mmcd.nmrfam.wisc.edu/ 
  
Compound data bases 
Name  URL 
Chemical Entities of Biological Interest (ChEBI) http://www.ebi.ac.uk/chebi/ 
PubChem https://pubchem.ncbi.nlm.nih.gov/# 
ChemSpider http://www.chemspider.com/ 
Ligand Expo http://ligand-expo.rcsb.org/ 
3DMET http://www.3dmet.dna.affrc.go.jp/ 
KNApSAcK (A Comprehensive Species-Metabolite Relationship 
Database) 
http://kanaya.naist.jp/KNApSAcK/ 
ZINC http://zinc.docking.org/ 
LIPID MAPS http://www.lipidmaps.org/ 
  
Pathway data bases 
Name  URL 
KEGG: Kyoto Encyclopedia of Genes and Genomes http://www.genome.jp/kegg/ 
The Small Molecule Pathway Database (SMPDB ) http://smpdb.ca/ 
BioCyc http://biocyc.org/ 
MetaCyc Metabolic Pathway Database http://metacyc.org/ 
Reactome http://www.reactome.org/ 
  
Comprehensive metabolomic data bases 
Name  URL 
KEGG: Kyoto Encyclopedia of Genes and Genomes http://www.genome.jp/kegg/ 
The Human Metabolome Database (HMDB) http://www.hmdb.ca/ 
Madison Metabolomics Consortium Database (MMCD) http://mmcd.nmrfam.wisc.edu/ 
DrugBank database http://www.drugbank.ca/ 
 
 
  
 Figure 1. PubMed data showing articles with the search words NMR and 
metabolomics or NMR and metabonomics. 
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Figure 2.  
1
H spectra of HT29 tumors, illustrating the improved resolution 
available from ex vivo spectra obtained by HR-MAS and tissue extraction. A. In 
vivo localized 
1
H MR spectrum of an HT29 tumor in a mouse. tCho, total choline; Cr, 
creatine.  B. HR-MAS 
1
H spectrum of an excised HT29 tumor. 1, lipids; 2, lactate; 3, 
alanine; 4, glutamate; 5, creatine + phosphocreatine; 6, choline-containing 
compounds; 7, taurine; 8, creatine + phosphocreatine.  C. In vitro 
1
H MR spectrum of 
a perchloric acid extract of a HT29 tumor. 1, lactate; 2, alanine; 3, glutamate; 4,  
Glutamine; 5, creatine + phosphocreatine; 6, phosphocholine+ 
glycerophosphocholine; 7, taurine; 8, glycine; 9, creatine; 10, phosphocreatine; 11, 
water; 12, glucose.  Adapted from YL Chung & JR Griffiths, Metabolomic Studies on 
Cancer and on Anticancer Drugs by NMR Ex Vivo, emrstm1093. 
  
  
 
  PCA      OPLS-DA 
   
   
Figure 3. PCA and OPLS-DA analysis of 
1
H NMR metabolite extract data from wild 
type and HIF-1a knockout astrocyte cells grown in normoxic and hypoxic conditions. 
Top panels: PCA and OPLS-DA scores plots from wild type (yellow-normoxia and red – 
hypoxia) and HIF-1a knockout astrocytes (Blue – normoxia and Green – hypoxia). There is a 
clearer separation of wild type and knock-out astrocyte cells grown at hypoxic conditions in 
the OPLS-DA plot (red and green circles). Bottom panels: loadings plots from both methods 
show that lactate and phosphocholine are mainly responsible for the separation of clusters in 
hypoxia.  
  
References: 
1.  B. Madhu, M. Dadulescu and J. Griffiths, MAGMA, 2014, 28, 161. 
2.  J. Folch, M. Lees and G. H. Sloane Stanley, J Biol Chem,  1957, 226, 497. 
3.  J. Henke, W. Willker, J. Engelmann and D. Leibfritz, Anticancer Res,  1996, 16, 1417. 
4.  O. Beckonert, M. Coen, H. C. Keun, Y. Wang, T. M. Ebbels, E. Holmes, J. C. Lindon and J. K. 
Nicholson, Nat Protoc,  2010, 5, 1019. 
5.  B.  Worley and R. Powers, Current Metabolomics, 2013, 1, 92. 
6.  E. J. Delikatny, S. Chawla, D. J. Leung and H. Poptani, NMR Biomed,  2011, 24, 592. 
7.  S. E. Day, M. I. Kettunen, F. A. Gallagher, D. E. Hu, M. Lerche, J. Wolber, K. Golman, J. H. 
Ardenkjaer-Larsen and K. M. Brindle, Nat Med,  2007, 13, 1382. 
8.  G. Lin, D. K. Hill, G. Andrejeva, J. K. Boult, H. Troy, A. C. Fong, M. R. Orton, R. Panek, H. G. Parkes, 
M. Jafar, D. M. Koh, S. P. Robinson, I. R. Judson, J. R. Griffiths, M. O. Leach, T. R. Eykyn and Y. L. 
Chung, Br J Cancer,  2014, 111, 375. 
9.  G. Lin, G. Andrejeva, A. C. Wong Te Fong, D. K. Hill, M. R. Orton, H. G. Parkes, D. M. Koh, S. P. 
Robinson, M. O. Leach, T. R. Eykyn and Y. L. Chung, PLoS One,  2014, 9, e92645. 
10.  D. Hanahan and R. A. Weinberg, Cell,  2011, 144, 646. 
11.  A. Schulze and A. L. Harris, Nature,  2012, 491, 364. 
12.  M. S. Palmnas and H. J. Vogel, Metabolites,  2013, 3, 373. 
13.  B. K. Sarkar, C. Chakraborty, A. R. Sharma, K. J. Bae, G. Sharma, G. P. Doss, D. Dutta, S. Ding, B. 
Ganbold, J. S. Nam and S. S. Lee, Front Biosci (Landmark Ed),  2014, 19, 1186. 
14.  M. Bulik, R. Jancalek, J. Vanicek, A. Skoch and M. Mechl, Clin Neurol Neurosurg,  2013, 115, 146. 
15.  S. Kundu, S. Chopra, A. Verma, U. Mahantshetty, R. Engineer and S. K. Shrivastava, J Cancer Res 
Ther,  2012, 8, 11. 
16.  W. Chen, Y. Zu, Q. Huang, F. Chen, G. Wang, W. Lan, C. Bai, S. Lu, Y. Yue and F. Deng, Magn 
Reson Med,  2011, 66, 1531. 
17.  P. J. Bolan, Magn Reson Imaging Clin N Am,  2013, 21, 625. 
18.  M. F. Penet, M. M. Gadiya, B. Krishnamachary, S. Nimmagadda, M. G. Pomper, D. Artemov and 
Z. M. Bhujwalla, Cancer Res,  2011, 71, 6948. 
19.  M. Stubbs, P. M. McSheehy, J. R. Griffiths and C. L. Bashford, Mol Med Today,  2000, 6, 15. 
20.  S. Biswas, H. Troy, R. Leek, Y. L. Chung, J. L. Li, R. R. Raval, H. Turley, K. Gatter, F. Pezzella, J. R. 
Griffiths, M. Stubbs and A. L. Harris, J Oncol,  2010, 2010, 757908. 
21.  C. S. Ward, H. S. Venkatesh, M. M. Chaumeil, A. H. Brandes, M. Vancriekinge, H. Dafni, S. 
Sukumar, S. J. Nelson, D. B. Vigneron, J. Kurhanewicz, C. D. James, D. A. Haas-Kogan and S. M. Ronen, 
Cancer Res,  2010, 70, 1296. 
22.  R. J. DeBerardinis, A. Mancuso, E. Daikhin, I. Nissim, M. Yudkoff, S. Wehrli and C. B. Thompson, 
Proc Natl Acad Sci U S A,  2007, 104, 19345. 
23.  H. Ashrafian, L. O'Flaherty, J. Adam, V. Steeples, Y. L. Chung, P. East, S. Vanharanta, H. Lehtonen, 
E. Nye, E. Hatipoglu, M. Miranda, K. Howarth, D. Shukla, H. Troy, J. Griffiths, B. Spencer-Dene, M. 
Yusuf, E. Volpi, P. H. Maxwell, G. Stamp, R. Poulsom, C. W. Pugh, B. Costa, C. Bardella, M. F. Di Renzo, 
M. I. Kotlikoff, V. Launonen, L. Aaltonen, M. El-Bahrawy, I. Tomlinson and P. J. Pollard, Cancer Res,  
2010, 70, 9153. 
24.  W. M. Linehan and T. A. Rouault, Clin Cancer Res,  2013, 19, 3345. 
25.  C. Choi, S. K. Ganji, R. J. DeBerardinis, K. J. Hatanpaa, D. Rakheja, Z. Kovacs, X. L. Yang, T. 
Mashimo, J. M. Raisanen, I. Marin-Valencia, J. M. Pascual, C. J. Madden, B. E. Mickey, C. R. Malloy, R. 
M. Bachoo and E. A. Maher, Nat Med,  2012, 18, 624. 
26.  M. M. Chaumeil, P. E. Larson, H. A. Yoshihara, O. M. Danforth, D. B. Vigneron, S. J. Nelson, R. O. 
Pieper, J. J. Phillips and S. M. Ronen, Nat Commun,  2013, 4, 2429. 
27.  M. M. Chaumeil, P. E. Larson, S. M. Woods, L. Cai, P. Eriksson, A. E. Robinson, J. M. Lupo, D. B. 
Vigneron, S. J. Nelson, R. O. Pieper, J. J. Phillips and S. M. Ronen, Cancer Res,  2014, 74, 4247. 
28.  Y. L. Chung, H. Troy, R. Kristeleit, W. Aherne, L. E. Jackson, P. Atadja, J. R. Griffiths, I. R. Judson, P. 
Workman, M. O. Leach and M. Beloueche-Babari, Neoplasia,  2008, 10, 303. 
29.  K. Glunde, Z. M. Bhujwalla and S. M. Ronen, Nat Rev Cancer,  2011, 11, 835. 
30.  J. L. Griffin, H. Atherton, J. Shockcor and L. Atzori, Nat Rev Cardiol,  2011, 8, 630. 
31.  C. J. Holloway, J. Suttie, S. Dass and S. Neubauer, Prog Cardiovasc Dis,  2011, 54, 320.  
32. R. Beadle and M. Frenneaux, Expert Rev Cardiovasc Ther, 2010, 8, 269. 
33.  Y. Yang, L. Yang, Y. Zhang, X. Gu, D. Xu, F. Fang, A. Sun, K. Wang, Y. Yu, J. Zuo and J. Ge, Exp Ther 
Med,  2013, 5, 683. 
34.  S. A. Perrine, M. S. Michaels, F. Ghoddoussi, E. M. Hyde, M. E. Tancer and M. P. Galloway, NMR 
Biomed,  2009, 22, 419. 
35.  O. J. Rider and D. J. Tyler, J Cardiovasc Magn Reson,  2013, 15, 93. 
36.  M. A. Schroeder, K. Clarke, S. Neubauer and D. J. Tyler, Circulation,  2011, 124, 1580. 
37.  M. Mayr, B. Metzler, Y. L. Chung, E. McGregor, U. Mayr, H. Troy, Y. Hu, M. Leitges, O. Pachinger, 
J. R. Griffiths, M. J. Dunn and Q. Xu, Am J Physiol Heart Circ Physiol,  2004, 287, H946. 
38. M. Mayr, Y. L. Chung, U. Mayr, E. McGregor, H. Troy, G. Baier, M. Leitges, M. J. Dunn, J. R. 
Griffiths and Q. Xu, Am J Physiol Heart Circ Physiol,  2004, 287, H937. 
39.  Mayr M, Zampetaki A, Sidibe A, Mayr U, Yin X, De Souza AI, Chung YL, Madhu B, Quax PH, Hu Y, 
Griffiths JR, Xu Q. Circ Res. 2008 , 102, 1046. 
40.  M. Mayr, S. Yusuf, G. Weir, Y. L. Chung, U. Mayr, X. Yin, C. Ladroue, B. Madhu, N. Roberts, A. De 
Souza, S. Fredericks, M. Stubbs, J. R. Griffiths, M. Jahangiri, Q. Xu and A. J. Camm, J Am Coll Cardiol,  
2008, 51, 585. 
41.  M. van der Graaf, Eur Biophys J,  2010, 39, 527. 
42.  S. Ramadan, A. Lin and P. Stanwell, NMR Biomed, 2013, 26, 1630. 
43.  L. S. de Vries and F. Groenendaal, Neuroradiology, 2010, 52, 555. 
44.  S. L. Risacher and A. J. Saykin, Semin Neurol, 2013, 33, 386.  
45. B. R. Sajja, J. S. Wolinsky and P. A. Narayana, Neuroimaging Clin N Am,  2009, 19, 45.  
46. N. Zhang, X. Song, R. Bartha, S. Beyea, R. D'Arcy, Y. Zhang and K. Rockwood, Curr Alzheimer Res,  
2014, 11, 367.  
47. S. Prabakaran, J. E. Swatton, M. M. Ryan, S. J. Huffaker, J. T. Huang, J. L. Griffin, M. Wayland, T. 
Freeman, F. Dudbridge, K. S. Lilley, N. A. Karp, S. Hester, D. Tkachev, M. L. Mimmack, R. H. Yolken, M. 
J. Webster, E. F. Torrey and S. Bahn, Mol Psychiatry,  2004, 9, 684. 
48.  L. L. Cheng, K. Newell, A. E. Mallory, B. T. Hyman and R. G. Gonzalez, Magn Reson Imaging,  
2002, 20, 527. 
49.  A. M. Jones, D. P. Wilkerson, F. DiMenna, J. Fulford and D. C. Poole, Am J Physiol Regul Integr 
Comp Physiol,  2008, 294, R585. 
50.  J. A. Kent-Braun, R. G. Miller and M. W. Weiner, Radiol Clin North Am,  1994, 32, 313.  
51. Z. Argov and D. L. Arnold, Neurol Clin,  2000, 18, 35, N. J. Olsen, J. H. Park and L. E. King, Jr., Curr 
Rheumatol Rep,  2001, 3, 346. 
52.  J. P. Mattei, D. Bendahan and P. Cozzone, Reumatismo,  2004, 56, 9.  
53. N. J. Olsen, L. E. King, Jr. and J. H. Park, Rheum Dis Clin North Am,  1996, 22, 783. 
54.  Y. L. Chung, H. Alexanderson, N. Pipitone, C. Morrison, M. Dastmalchi, C. Stahl-Hallengren, S. 
Richards, E. L. Thomas, G. Hamilton, J. D. Bell, I. E. Lundberg and D. L. Scott, Arthritis Rheum,  2007, 
57, 694. 
55.  B. Madhu, K. Lagerwall and B. Soussi, NMR Biomed, 1996, 9, 327. 
56.  G. J. Kemp, M. Meyerspeer and E. Moser, NMR Biomed, 2007, 20, 555. 
57.  C. Boesch and R. Kreis, Ann N Y Acad Sci, 2000, 904, 25. 
58.  J. Machann, N. Stefan and F. Schick, Eur J Radiol, 2008, 67, 275. 
59.  J. Dube and B. H. Goodpaster, Curr Opin Clin Nutr Metab Care,  2006, 9, 553. 
 
 
 
